[Minocycline-containing eradication therapy for patients with clarithromycin-resistant Helicobacter pylori infection].
Sato
Ryugo
R
Second Department of Internal Medicine, Oita Medical University.
Murakami
Kazunari
K
Okimoto
Tadayoshi
T
Ishitobi
Hirokazu
H
Nasu
Masaru
M
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles / Q000627:therapeutic use; D017291:Clarithromycin; D004334:Drug Administration Schedule; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D008795:Metronidazole / Q000627:therapeutic use; D008911:Minocycline / Q000494:pharmacology / Q000627:therapeutic use*; D009853:Omeprazole / Q000031:analogs & derivatives; D064750:Rabeprazole; D017211:Treatment Failure
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles; D008795:Metronidazole; D064750:Rabeprazole; D008911:Minocycline; D017291:Clarithromycin; D009853:Omeprazole